GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Biocept Inc (STU:B00) » Definitions » 3-Year FCF Growth Rate

Biocept (STU:B00) 3-Year FCF Growth Rate : 58.30% (As of Jun. 2023)


View and export this data going back to 2015. Start your Free Trial

What is Biocept 3-Year FCF Growth Rate?

Biocept's Free Cash Flow per Share for the three months ended in Jun. 2023 was €-2.83.

During the past 3 years, the average Free Cash Flow per Share Growth Rate was 58.30% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Free Cash Flow per Share growth rate.

During the past 12 years, the highest 3-Year average Free Cash Flow per Share Growth Rate of Biocept was 80.50% per year. The lowest was 45.40% per year. And the median was 58.30% per year.


Competitive Comparison of Biocept's 3-Year FCF Growth Rate

For the Diagnostics & Research subindustry, Biocept's 3-Year FCF Growth Rate, along with its competitors' market caps and 3-Year FCF Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Biocept's 3-Year FCF Growth Rate Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Biocept's 3-Year FCF Growth Rate distribution charts can be found below:

* The bar in red indicates where Biocept's 3-Year FCF Growth Rate falls into.



Biocept 3-Year FCF Growth Rate Calculation

This is the 3-year average growth rate of Free Cash Flow per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Free Cash Flow per Share growth rate.


Biocept  (STU:B00) 3-Year FCF Growth Rate Explanation

Free Cash Flow per Share is the amount of Free Cash Flow per outstanding share of the company's stock. Free Cash Flow is considered one of the most important parameters to measure a company's earnings power by value investors because it is not subject to estimates of Depreciation, Depletion and Amortization (DDA). However, when we look at the Free Cash Flow, we should look from a long term perspective, because any year's Free Cash Flow can be drastically affected by the spending on Property, Plant, & Equipment (PPE) of the business in that year. Over the long term, Free Cash Flow should give pretty good picture on the real earnings power of the company. It's used in the calculation of Forward Rate of Return (Yacktman) %.


Biocept 3-Year FCF Growth Rate Related Terms

Thank you for viewing the detailed overview of Biocept's 3-Year FCF Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.


Biocept (STU:B00) Business Description

Traded in Other Exchanges
Address
9955 Mesa Rim Road, San Diego, CA, USA, 92121
Biocept Inc develops and commercializes molecular diagnostic assays that provide physicians with clinically actionable information for treating and monitoring patients diagnosed with a variety of cancers. In addition to its portfolio of blood-based liquid biopsy assays, Biocept has developed the CNSide cerebrospinal fluid assay that detects cancer that has metastasized to the central nervous system. Biocept's patented Target Selector technology captures and quantitatively analyzes CSF tumor cells for tumor-associated molecular markers, using technology first developed for use in blood. It is also leveraging its molecular diagnostic capabilities to offer nationwide COVID-19 RT-PCR testing to support public health efforts during this unprecedented pandemic.

Biocept (STU:B00) Headlines

No Headlines